Drug profile · INN
baricitinib
OLUMIANT
baricitinib (OLUMIANT) is a tyrosine-protein kinase jak2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — baricitinib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- ORAL
- Patents
- 0
- Programs
- 20
- Data quality
- 0.84
Quick answer
baricitinib (OLUMIANT) is a tyrosine-protein kinase jak2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Tyrosine-protein kinase JAK2 inhibitor
Primary target: Tyrosine-protein kinase JAK1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
| NMPA | clinical trials | — |
Congress & event coverage
- PresentationPharma Manufacturing World
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is baricitinib?
baricitinib (OLUMIANT) is a tyrosine-protein kinase jak2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for baricitinib?
OLUMIANT is a marketed brand name for baricitinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of baricitinib?
baricitinib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.